MIFID II May Hit Small & Midcap EU Biotech Investment
New EU regulation designed to offer greater protection and more transparency for investors could have serious implications for Europe’s small to midcap biotechs just as the European Investment Bank predicts a potential €40bn funding shortfall in key bioclusters by 2021.
You may also be interested in...
Analysis by the European Investment Bank predicts that EU biotechs face a funding shortfall of up to €40bn by 2021. Barbara Freischem, executive director of European Biopharmaceutical Enterprises, who moderated a panel on the topic at BIO-Europe Spring 2018, talked to Scrip about initiatives that could alleviate the shortfall.
Cambridge, UK-based Healx has concluded a $56m series B round, led by Atomico, to put up to 50 potential rare disease treatments into the clinic within two years using its AI/ML platform.
Tapping into the ability of arenaviruses to deliver prolonged local immune activation, rapid regression of localized and metastatic cancers, and long-term disease control, Essen, Germany-based start-up Abalos Therapeutics has raised €12m to advance its lead candidates towards clinical testing.